Serum Hyaluronan in Patients With Multiple Myeloma: Correlation With Survival and Ig Concentration

Serum from 386 myeloma patients were analyzed for serum hyaluronan (HYA) at diagnosis. Median age was 68 years (range, 32 to 87 years). The distribution of Ig classes was typical (58% IgG, 21% IgA, 1% IgD, and 20% light chain disease). The patients comprised 58% in stage III, 33% in stage II, and 9%...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1999-06, Vol.93 (12), p.4144-4148
Main Authors: Dahl, Inger Marie S., Turesson, Ingemar, Holmberg, Erik, Lilja, Karin
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
beta 2-Microglobulin - analysis
Biological and medical sciences
Female
Hemoglobins - analysis
Humans
Hyaluronic Acid - blood
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulin A - blood
Immunoglobulin D - blood
Immunoglobulin G - blood
Immunoglobulinopathies
Immunoglobulins - blood
Immunopathology
Male
Medical sciences
Middle Aged
Multiple Myeloma - blood
Multiple Myeloma - immunology
Multiple Myeloma - mortality
Reference Values
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Serum from 386 myeloma patients were analyzed for serum hyaluronan (HYA) at diagnosis. Median age was 68 years (range, 32 to 87 years). The distribution of Ig classes was typical (58% IgG, 21% IgA, 1% IgD, and 20% light chain disease). The patients comprised 58% in stage III, 33% in stage II, and 9% in stage I. The majority (82%) had HYA values within an intermediate range (10 to 120 μg/L), 13% had high values (>120 μg/L), and 5% had abnormally low values (0 to 9 μg/L). For the first time, a patient group with abnormally low HYA serum values is reported. An inverse correlation between survival and HYA serum level was found (P = .015). When tested separately, patients with abnormally low or high HYA values had significantly shorter median survival (21.1 and 19.7 months, respectively) than those with an intermediate HYA concentration (32.6 months; P = .005). Patients with abnormally low or high HYA levels had more advanced disease as judged by staging and biochemical markers. Interestingly, there was an inverse correlation between the HYA value and the M-component concentration in serum. Fifty percent of patients with abnormally low HYA values had IgA myelomas. In conclusion, the serum concentration of HYA may be of prognostic value in selected cases of multiple myeloma. Further studies will be performed to elucidate possible explanations for our findings, especially those related to the HYA cell surface binding proteins.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V93.12.4144